GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medite Cancer Diagnostics Inc (OTCPK:MDIT) » Definitions » Beta

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Beta : 139.63 (As of Jun. 19, 2024)


View and export this data going back to . Start your Free Trial

What is Medite Cancer Diagnostics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-19), Medite Cancer Diagnostics's Beta is 139.63.


Medite Cancer Diagnostics Beta Historical Data

The historical data trend for Medite Cancer Diagnostics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medite Cancer Diagnostics Beta Chart

Medite Cancer Diagnostics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.50 -1.34 -2.03 -2.32 -0.32

Medite Cancer Diagnostics Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.32 -0.82 0.07 0.04

Competitive Comparison of Medite Cancer Diagnostics's Beta

For the Medical Instruments & Supplies subindustry, Medite Cancer Diagnostics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medite Cancer Diagnostics's Beta Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medite Cancer Diagnostics's Beta distribution charts can be found below:

* The bar in red indicates where Medite Cancer Diagnostics's Beta falls into.



Medite Cancer Diagnostics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Medite Cancer Diagnostics  (OTCPK:MDIT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Medite Cancer Diagnostics Beta Related Terms

Thank you for viewing the detailed overview of Medite Cancer Diagnostics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Medite Cancer Diagnostics (Medite Cancer Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
4203 SouthWest 34th Street, Orlando, FL, USA, 32811
Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.
Executives
Lewis William Austin Iv director, 10 percent owner 201 E 87TH STREET, APT 5H, NEW YORK NY 10128
John H Abeles director 2365 NW 41ST STREET BOCA RATON FL 33431
Joel S Kanter director C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Clinton Severson director C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587

Medite Cancer Diagnostics (Medite Cancer Diagnostics) Headlines

No Headlines